BioCentury | Dec 14, 2015
Financial News

Sygnis Pharma completes rights offering

Sygnis Pharma AG (Xetra:LIO1), Heidelberg, Germany Business: Genomics, Supply/Service Date completed: 2015-12-10 Type: Rights offering Raised: EUR5.6 million ($6.1 million) Shares: 3 million Price: EUR1.90 Shares after offering: 16.8 million Investors: Existing investors; institutional investors...
BioCentury | Nov 23, 2015
Financial News

Sygnis Pharma proposes rights offering

Sygnis Pharma AG (Xetra:LIO1), Heidelberg, Germany Business: Genomics, Supply/Service Date announced: 2015-11-17 Type: Rights offering To be raised: Up to EUR7.3 million ($7.9 million) Shares: 3.9 million Price: EUR1.90 Shares outstanding prior: 13.5 million Investor:...
BioCentury | Jun 4, 2015
Company News

Management tracks

...India). Oncology company Apogenix GmbH (Heidelberg, Germany) named Peter Willinger CFO. He was CFO of Sygnis Pharma AG...
BioCentury | Dec 22, 2014
Financial News

Sygnis Pharma completes rights offering

Sygnis Pharma AG (Xetra:LIO1), Heidelberg, Germany Business: Genomics, Supply/Service Date completed: 2014-12-12 Type: Rights offering Raised: EUR5 million ($6.2 million) Shares: 2.5 million Price: €2 Shares after offering: 13.2 million Investor: Existing investors Note: Shareholders...
BioCentury | May 19, 2014
Company News

Sygnis Pharma, Systasy deal

...payments and be eligible for royalties, but the companies are not disclosing further financial terms. Sygnis Pharma AG...
BioCentury | Mar 17, 2014
Finance

Circassia raises expectations

...billion). No European biotech IPO has come close to the Circassia deal since 2000, when Lion bioscience...
...IPO on Xetra. After selling off its bioinformatics assets, Lion was reincarnated in 2006 as Sygnis Pharma AG...
...Group plc (LSE:RNVO), Manchester, U.K. Sanofi (Euronext:SAN; NYSE:SNY), Paris, France Stallergenes S.A. (Euronext:GENP), Antony, France Sygnis Pharma AG...
BioCentury | Dec 23, 2013
Financial News

Sygnis Pharma completes rights offering

Sygnis Pharma AG (Xetra: LIO1), Heidelberg, Germany Business: Diagnostic Date completed: 12/18/13 Type: Rights offering Raised: €400,741 ($551,219) Shares: 151,223 Price: €2.65 Shares after offering: 10.5 million Investors: Existing investors Note: Sygnis raised €400,741 ($551,219)...
BioCentury | Nov 4, 2013
Financial News

Sygnis Pharma completes rights offering

Sygnis Pharma AG (Xetra: LIO1), Heidelberg, Germany Business: Diagnostic Date completed: 10/28/13 Type: Rights offering Raised: €2.7 million ($3.7 million) Shares: 1 million Price: €2.65 Shares after offering: 10.4 million Investors: Existing investors; institutional investors...
BioCentury | Jul 15, 2013
Financial News

Sygnis Pharma completes debt financing

Sygnis Pharma AG (Xetra:LIO1), Heidelberg, Germany Business: Diagnostic Date completed: 7/8/13 Type: Debt financing Raised: €550,000 ($705,320) Investors: Bedford Investment Fund; The Excalibur Investments Fund; Casticapital; company director Note: The financing is a secured loan....
BioCentury | Jan 7, 2013
Finance

4Q Stock Wrap-Up: Go big or go home

...cash and investments at YE12, which BioCryst says will provide 15-18 months of runway 12/20/12 Sygnis Pharma AG...
Items per page:
1 - 10 of 273
BioCentury | Dec 14, 2015
Financial News

Sygnis Pharma completes rights offering

Sygnis Pharma AG (Xetra:LIO1), Heidelberg, Germany Business: Genomics, Supply/Service Date completed: 2015-12-10 Type: Rights offering Raised: EUR5.6 million ($6.1 million) Shares: 3 million Price: EUR1.90 Shares after offering: 16.8 million Investors: Existing investors; institutional investors...
BioCentury | Nov 23, 2015
Financial News

Sygnis Pharma proposes rights offering

Sygnis Pharma AG (Xetra:LIO1), Heidelberg, Germany Business: Genomics, Supply/Service Date announced: 2015-11-17 Type: Rights offering To be raised: Up to EUR7.3 million ($7.9 million) Shares: 3.9 million Price: EUR1.90 Shares outstanding prior: 13.5 million Investor:...
BioCentury | Jun 4, 2015
Company News

Management tracks

...India). Oncology company Apogenix GmbH (Heidelberg, Germany) named Peter Willinger CFO. He was CFO of Sygnis Pharma AG...
BioCentury | Dec 22, 2014
Financial News

Sygnis Pharma completes rights offering

Sygnis Pharma AG (Xetra:LIO1), Heidelberg, Germany Business: Genomics, Supply/Service Date completed: 2014-12-12 Type: Rights offering Raised: EUR5 million ($6.2 million) Shares: 2.5 million Price: €2 Shares after offering: 13.2 million Investor: Existing investors Note: Shareholders...
BioCentury | May 19, 2014
Company News

Sygnis Pharma, Systasy deal

...payments and be eligible for royalties, but the companies are not disclosing further financial terms. Sygnis Pharma AG...
BioCentury | Mar 17, 2014
Finance

Circassia raises expectations

...billion). No European biotech IPO has come close to the Circassia deal since 2000, when Lion bioscience...
...IPO on Xetra. After selling off its bioinformatics assets, Lion was reincarnated in 2006 as Sygnis Pharma AG...
...Group plc (LSE:RNVO), Manchester, U.K. Sanofi (Euronext:SAN; NYSE:SNY), Paris, France Stallergenes S.A. (Euronext:GENP), Antony, France Sygnis Pharma AG...
BioCentury | Dec 23, 2013
Financial News

Sygnis Pharma completes rights offering

Sygnis Pharma AG (Xetra: LIO1), Heidelberg, Germany Business: Diagnostic Date completed: 12/18/13 Type: Rights offering Raised: €400,741 ($551,219) Shares: 151,223 Price: €2.65 Shares after offering: 10.5 million Investors: Existing investors Note: Sygnis raised €400,741 ($551,219)...
BioCentury | Nov 4, 2013
Financial News

Sygnis Pharma completes rights offering

Sygnis Pharma AG (Xetra: LIO1), Heidelberg, Germany Business: Diagnostic Date completed: 10/28/13 Type: Rights offering Raised: €2.7 million ($3.7 million) Shares: 1 million Price: €2.65 Shares after offering: 10.4 million Investors: Existing investors; institutional investors...
BioCentury | Jul 15, 2013
Financial News

Sygnis Pharma completes debt financing

Sygnis Pharma AG (Xetra:LIO1), Heidelberg, Germany Business: Diagnostic Date completed: 7/8/13 Type: Debt financing Raised: €550,000 ($705,320) Investors: Bedford Investment Fund; The Excalibur Investments Fund; Casticapital; company director Note: The financing is a secured loan....
BioCentury | Jan 7, 2013
Finance

4Q Stock Wrap-Up: Go big or go home

...cash and investments at YE12, which BioCryst says will provide 15-18 months of runway 12/20/12 Sygnis Pharma AG...
Items per page:
1 - 10 of 273